France grapples with tropical diseases amid spread of tiger mosquitoes
French regions are waging war against tiger mosquitoes as the country records rising cases of tropical diseases such as dengue, zika and chikungunya.
Since Jan. 1, France has already seen 1,123 imported cases of dengue, 728 imported cases of chikungunya and four imported cases of zika. In May alone, French health authorities said they recorded 225 cases of chikungunya, 152 cases of dengue and one case of zika — also all imported.
The numbers raise alarm for health authorities, who are warning people to watch out for tiger mosquitoes, the insects most responsible for carrying and spreading the diseases.
Advertisement
While a person infected with dengue or chikungunya cannot pass the virus to another person, they can infect other mosquitoes, which can further spread the disease. Zika can be transmitted from an infected person through sexual intercourse.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
38 minutes ago
- Medscape
Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday. In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (NAION). But this is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. NAION is the second-most common cause of blindness due to optic nerve damage, after glaucoma. "This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns," said Barclays analyst Emily Field. U.S.-listed shares of the Danish drugmaker were up nearly 2.5% in early trading. The EMA, which started its review in December, has asked Novo to add NAION as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The "benefit-risk profile of semaglutide remains favorable," the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust CEO Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about $150 billion by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing NAION by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing NAION more than doubled after two years of treatment with Ozempic, compared to patients taking medicines from other classes. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. (Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Medscape
an hour ago
- Medscape
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial. Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects. 'Safety's been a key consideration with these drugs,' study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News . Sibeprenlimab represents a new mechanism of action and 'we don't yet fully understand the profile, so we've been looking at that data very carefully,' explained Perkovic. 'In particular, the infection risk has been my biggest concern, given we know that infections are dramatically increased in people with steroid therapy for example, in IgA nephropathy.' The results of the trial — the largest to date in the field — were presented at the 62nd European Renal Association Congress 2025 on June 6 and drew a warm applause from the audience. An Underestimated Condition IgA nephropathy is estimated to affect 2.5 per 100,000 people per year, although 'it's possible that that number is a significant underestimate,' said Perkovic. Diagnosis typically occurs between 20 and 40 years of age. And, despite supportive care, the majority of patients have a high lifetime risk of end-stage kidney disease (ESKD), with up to 50% of patients progressing to ESKD within 20 years of their clinical presentation. 'It's quite likely we've underestimated just how important this condition is,' said Perkovic, but 'we're fortunate that we're in the middle of something of a golden age of developing new treatments.' A number of therapies have been shown to reduce the risks associated with the disease, although they do not necessarily address the immunological basis of the condition. In addition to newer treatments, 'corticosteroids have long been used for people with IgA nephropathy,' Perkovic said, 'but of course, corticosteroids also have a range of different effects across the immune system,' which can lead to adverse outcomes. Sibeprenlimab is a selective IgG2 antibody that binds to and inhibits the biological activity of APRIL (a proliferation-inducing ligand), which is produced by mucosal epithelial and myeloid cells and binds to B cells. APRIL regulates B-cell-mediated immune responses and mediates IgG and IgA class switching in mature B cells. It is these two actions that make APRIL a key factor in the so-called 4-Hit process in the pathogenesis of IgA nephropathy, which results in the deposition of immune complexes in the glomerulus, leading to proteinuria and loss of kidney function. Phase 3 VISIONARY TRIAL Following on from the successful phase 2 ENVISION trial of sibeprenlimab, the researchers undertook the phase 3 VISIONARY trial, an ongoing study involving patients with biopsy-confirmed IgA nephropathy from 240 sites in 31 countries, who were randomized to sibeprenlimab or placebo for 100 weeks and followed up for a further 12 weeks. All patients were required to have a uPCR of ≥ 0.75 g/g or urine protein excretion of ≥ 1.0 g/day, an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2, and to have been on a stable dose of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a SGLT2 inhibitor, for ≥ 3 months prior to screening. For the current pre-specified interim analysis, Perkovic reported the efficacy and safety results in the first 320 randomized patients (152 in the sibeprenlimab group and 168 in the placebo group), focusing on the primary endpoint of 24-hour uPCR at 9 months vs baseline, with eGFR and other data expected to be presented in 2026. The median age of the patients was 42-43 years. There were proportionally fewer females in the sibeprenlimab group (34.2%) vs the placebo group (40.5%). The majority of the patients were Asian, at 61.8% and 56.5%, respectively. Compared with a rise in uPCR at the 9-month follow-up in the placebo group, sibeprenlimab was associated with a 50.2% reduction in uPCR, giving a highly significant placebo-adjusted treatment effect of 51.2% ( P < .0001). Importantly, the benefit of sibeprenlimab on uPCR was seen as early as 4 weeks after initiating treatment and continued to accrue throughout follow-up. Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, who co-chaired the session, told Medscape Medical News that the results look 'very promising.' 'Recently, we have had several agents working in different ways that all show proteinuria lowering,' he continued, but the results from those studies show that the improvements seen in VISIONARY are 'the best proteinuria lowering' seen so far. Gansevoort noted, however, that this remains an interim analysis, and that he is really looking forward to seeing the kidney function results, adding: 'It was a little bit of a pity that they were not allowed to show at least the 9-month interim data on kidney function, which would have been so interesting.' Safety Results In terms of safety, the proportion of patients experiencing a treatment-related treatment-emergent adverse event (TEAE) was marginally lower with sibeprenlimab, at 32.9% vs 31.0% with placebo. The proportion of patients having a TEAE that led to treatment discontinuation was 0.7% vs 2.4%, respectively, and there were fewer severe and serious TEAEs with the experimental drug. 'If we focus on the infection-related adverse events,' Perkovic said, 'we can see that rates were numerically slightly higher in the sibeprenlimab than the placebo group, with a pattern that was broadly consistent, but with perhaps a slight excess of COVID 19.' He noted that this was 'the reverse of the pattern we've seen in the phase 2 trials, suggesting a chance' outcome. 'The data so far look remarkably encouraging,' he added. There's really no suggestion of an increased risk of infection,' with no opportunistic infections identified, 'and certainly no deaths.' More data is required from the ongoing follow-up to support what has been observed so far, but if the final results do bear out both the efficacy and safety outcome, it will show that sibeprenlimab is 'a precision approach to the fundamental abnormality in IgA nephropathy: that's the really exciting part,' said Perkovic. The study was funded by Otsuka Pharmaceutical Development and Commercialization. Perkovic declares relationships with Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chinook Therapeutics, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Guard Therapeutics, Incyte, Janssen, Merck, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Shaanxi Micot Technology, Travere Therapeutics.
Yahoo
an hour ago
- Yahoo
The best ways to repel mosquitoes and prevent bites. Avoid contracting these illnesses
On warm summer nights in Louisiana, constantly swatting at pesky mosquitoes and itching bites can easily make your mood turn sour. Mosquitoes are often a significant problem during warmer months in Louisiana, as the state has high mosquito populations because of the hot, humid climate and numerous bodies of water. Mosquitoes can be not only annoying, but they can also pose health risks to humans by being transmitters of a number of various illnesses. Mosquitoes can carry various diseases and viruses, and may transmit these illnesses when the insect bites and injects saliva containing pathogens into the host's blood. Illnesses transmitted by mosquitoes can range in severity from mid to life-threatening. Common types of mosquito-borne diseases include malaria, dengue, West Nile virus, chikungunya, yellow fever, Western Equine Encephalitis and Zika, according to World Mosquito Program. Malaria is a serious and sometimes fatal mosquito-borne disease caused by a parasite spread by infected mosquitoes. In some instances, the illness can be treated with antimalarial drugs, says the Texas Department of State Health Services. Dengue is a disease caused by any of four closely-related dengue viruses, and severe dengue could have potentially deadly complications. People who get dengue a second time can become much sicker than the first time they had Dengue. Transmission is common is tropical and subtropical climates, according to the Texas Department of State Health Services. Zika virus spreads primarily through bites from certain mosquito types, and transmission is common in tropical and subtropical climates. Most people don't develop symptoms, but can still pass the virus to others. Symptoms are usually mild and last several days to a week, according to the Texas Department of State Health Services. Chikungunya is a disease caused by the chikungunya virus, which commonly occurs in tropical and subtropical areas. Most people feel better within a week, however, in some people, joint paint may persist. Death is uncommon, says the Texas Department of State Health Services. West Nile virus is spread by the bite of an infected mosquito and is not passed from person to person. Most infected people will not develop symptoms, however, they can develop mild to severe symptoms and, though uncommon, death can occur, according to the Texas Department of State Health Services. Yellow fever is a viral disease that typically has a short duration and symptoms tend to improve within five days, however, approximately 30,000 people around the world die from yellow fever every year. Jaundice can affect some patients, says the World Mosquito Program. Western Equine Encephalitis is a viral illness that is transmitted to people and horses through bite of an infected mosquito. Most people infected with this virus will not become ill, however, others may develop a mild illness. A small percentage of people may require hospitalization, says the Texas Department of State Health Services. In order to effectively prevent and repel mosquitoes, the CDC recommends combining personal protection measures with environmental control. Using EPA-approved insect repellents containing DEET, picaridin or oil of lemon eucalyptus helps prevent mosquito bites. Additionally, natural repellents like citronella, essential oils and garlic can prevent mosquitoes. Covering exposed skin by wearing long-sleeved shirts, long pants and socks is also recommended. Clothing can also be treated with permethrin, which is a pesticide that repels insects when applied to fabric, according to Brown University Health. Any containers that hold water should regularly be checked, emptied or scrubbed in order to eliminate standing water. Moving water should be maintained within water features, however, if mosquitoes can't seem to be rid from a water source, Mosquito Dunks can be used. Mosquito Dunks are small tablets that contain a naturally occurring bacterium that is toxic to mosquito larvae, but not harmful to humans, pets or other wildlife. The tablets float on the surface of standing water and slowly release the bacterium, killing the mosquito larvae that consume it. Presley Bo Tyler is a reporter for the Louisiana Deep South Connect Team for Gannett/USA Today. Find her on X @PresleyTyler02 and email at PTyler@ This article originally appeared on Shreveport Times: What viruses do mosquitoes carry? How many can be deadly? What to know
